Hutchmed (china) Limited (HCM) RNS Announcements

Date	Time	Date	TitleTitle (filtered)	Source
29/09/23	09:30:02	29 Sept 2023	NDA Submission for Fruquintinib in Japan	NDA Submission for Fruquintinib in Japan	RNS
29/09/23	09:30:02	29 Sept 2023	Total Voting Rights	Total Voting Rights	RNS
14/09/23	09:30:03	14 Sept 2023	Director’s Share Dealing	Director’s Share Dealing	RNS
12/09/23	09:30:02	12 Sept 2023	Phase IIIb Savolitinib Results at WCLC 2023	Phase IIIb Savolitinib Results at WCLC 2023	RNS
12/09/23	07:00:07	12 Sept 2023	Patient Enrollment Completed for Bridging Study	Patient Enrollment Completed for Bridging Study	RNS
31/08/23	09:30:02	31 Aug 2023	Total Voting Rights	Total Voting Rights	RNS
29/08/23	07:00:08	29 Aug 2023	BTD in China for Savolitinib for Gastric Cancer	BTD in China for Savolitinib for Gastric Cancer	RNS
21/08/23	07:00:04	21 Aug 2023	Sovleplenib Phase 3 Study Meets Primary Endpoint	Sovleplenib Phase 3 Study Meets Primary Endpoint	RNS
07/08/23	09:30:01	7 Aug 2023	Exercise of Share Options by a Director	Exercise of Share Options by a Director	RNS
31/07/23	12:00:01	31 Jul 2023	Interim Results and Business Updates	Interim Results and Business Updates	RNS
20/07/23	07:00:09	20 Jul 2023	Breakthrough Therapy Designation for Fruquintinib	Breakthrough Therapy Designation for Fruquintinib	RNS
13/07/23	09:30:01	13 Jul 2023	Changes to Board and Technical Committee	Changes to Board and Technical Committee	RNS
10/07/23	07:00:07	10 Jul 2023	Phase 1 Study of HMPL-415 Initiated	Phase 1 Study of HMPL-415 Initiated	RNS
29/06/23	09:30:00	29 Jun 2023	Blocklisting Six Monthly Return	Blocklisting Six Monthly Return	RNS
26/06/23	09:30:01	26 Jun 2023	HUTCHMED to Announce 2023 Half-Year Results	HUTCHMED to Announce 2023 Half-Year Results	RNS
16/06/23	07:00:05	16 Jun 2023	Phase III FRESCO-2 Results in The Lancet	Phase III FRESCO-2 Results in The Lancet	RNS
15/06/23	15:39:19	15 Jun 2023	MAA of Fruquintinib Validated by the EMA	MAA of Fruquintinib Validated by the EMA	RNS
09/06/23	10:30:03	9 Jun 2023	HUTCHMED Highlights Presentations at EHA and ICML	HUTCHMED Highlights Presentations at EHA and ICML	RNS
06/06/23	10:00:01	6 Jun 2023	LTIP and Share Option Scheme	LTIP and Share Option Scheme	RNS
31/05/23	09:30:00	31 May 2023	Total Voting Rights	Total Voting Rights	RNS
26/05/23	07:00:06	26 May 2023	Fruquintinib NDA Granted Priority Review by FDA	Fruquintinib NDA Granted Priority Review by FDA	RNS
26/05/23	07:00:06	26 May 2023	HUTCHMED Highlights Presentations at ASCO 2023	HUTCHMED Highlights Presentations at ASCO 2023	RNS
17/05/23	09:30:02	17 May 2023	Standard form for notification of major holdings	Standard form for notification of major holdings	RNS
12/05/23	13:15:01	12 May 2023	Annual General Meeting Poll Results	Annual General Meeting Poll Results	RNS
12/05/23	09:30:01	12 May 2023	Board of Directors and Board Committee Membership	Board of Directors and Board Committee Membership	RNS
10/05/23	09:30:01	10 May 2023	Appointment of Independent NED	Appointment of Independent NED	RNS
28/04/23	09:30:01	28 Apr 2023	Total Voting Rights	Total Voting Rights	RNS
21/04/23	09:30:00	21 Apr 2023	Vesting of awards under the LTIP	Vesting of awards under the LTIP	RNS
18/04/23	07:00:07	18 Apr 2023	NDA Acceptance in China for Fruquintinib	NDA Acceptance in China for Fruquintinib	RNS
12/04/23	07:00:07	12 Apr 2023	Presentations at AACR Annual Meeting 2023	Presentations at AACR Annual Meeting 2023	RNS
11/04/23	09:30:02	11 Apr 2023	Intended Retirement of Independent NED	Intended Retirement of Independent NED	RNS
11/04/23	09:30:02	11 Apr 2023	2022 Annual Report and Notice of AGM	2022 Annual Report and Notice of AGM	RNS
04/04/23	10:30:01	4 Apr 2023	HUTCHMED Initiates Registration Phase Enrollments	HUTCHMED Initiates Registration Phase Enrollments	RNS
31/03/23	09:30:01	31 Mar 2023	Total Voting Rights	Total Voting Rights	RNS
31/03/23	07:00:11	31 Mar 2023	Rolling Submission of Fruquintinib US NDA Complete	Rolling Submission of Fruquintinib US NDA Complete	RNS
14/03/23	13:30:01	14 Mar 2023	Closing of Fruquintinib License to Takeda	Closing of Fruquintinib License to Takeda	RNS
08/03/23	08:30:02	8 Mar 2023	Director's Share Dealing	Director's Share Dealing	RNS
06/03/23	08:30:02	6 Mar 2023	Vesting of awards under the LTIP	Vesting of awards under the LTIP	RNS
28/02/23	12:15:02	28 Feb 2023	Publication of Form 20-F	Publication of Form 20-F	RNS
28/02/23	08:30:01	28 Feb 2023	2022 Full Year Results and Business Updates	2022 Full Year Results and Business Updates	RNS
27/02/23	10:00:05	27 Feb 2023	Enrollment Completed in Phase 2 Amdizalisib trial	Enrollment Completed in Phase 2 Amdizalisib trial	RNS
31/01/23	08:30:02	31 Jan 2023	Notice of Results	Notice of Results	RNS
23/01/23	08:00:01	23 Jan 2023	License to Takeda for Fruquintinib outside China	License to Takeda for Fruquintinib outside China	RNS
18/01/23	14:30:02	18 Jan 2023	Inclusion of ORPATHYS in NRDL in China	Inclusion of ORPATHYS in NRDL in China	RNS
03/01/23	08:30:01	3 Jan 2023	Enrollment Completed in Phase 3 Trial	Enrollment Completed in Phase 3 Trial	RNS
30/12/22	08:30:05	30 Dec 2022	Blocklisting Six Monthly Return	Blocklisting Six Monthly Return	RNS
19/12/22	10:00:01	19 Dec 2022	FDA NDA Rolling Submission for Fruquintinib	FDA NDA Rolling Submission for Fruquintinib	RNS
15/11/22	07:00:05	15 Nov 2022	HUTCHMED Announces Strategy Update	HUTCHMED Announces Strategy Update	RNS
14/11/22	07:00:06	14 Nov 2022	Positive Topline Phase 3 Result in Fruquintinib	Positive Topline Phase 3 Result in Fruquintinib	RNS
27/10/22	12:30:01	27 Oct 2022	HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib	HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib	RNS

Showing 151–200 of 269 announcements

Hutchmed (china) Limited RNS

Hutchmed (china) Limited RNS